Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1677 1678 1682 1758
This examiner grants 30% of resolved cases
Alexander Alexandrovic Volkov is an examiner in Tech Center 1700 and Art Unit 1677. The examiner has 95 resolved cases in the current dataset. The allowance rate is 29.5%. The median time to reach an allowance is 1481 days. These figures provide a baseline for practitioners evaluating their prospects in this art unit. The 95 resolved cases offer a data-driven look at the typical prosecution path.
The interview lift is 21.5%. This metric indicates that an interview increases the probability of success compared to the 29.5% baseline. The 1481 days to allowance is the median duration for cases that issued. Practitioners can compare the 21.5% interview lift to the baseline to determine the value of direct communication. With 95 resolved cases, the allowance rate of 29.5% is a primary indicator of the examiner's disposition. The 1481 days to allowance provides a timeframe for reaching a final decision. This data from Art Unit 1677 helps in developing a strategy for Tech Center 1700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18452029 | IMMUNOCHROMATOGRAPHIC ASSAY APPARATUS | Final Rejection | FUJIFILM Corporation |
| 16962246 | PERIODONTAL DISEASE DIAGNOSTIC METHODS, USES AND KITS | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 18573224 | METHODS AND MATERIALS FOR TREATING CANCER | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18017563 | DUAL BARCODE INDEXES FOR MULTIPLEX SEQUENCING OF ASSAY SAMPLES SCREENED WITH MULTIPLEX INSOLUTION PROTEIN ARRAY | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18561331 | METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17982901 | COMPOSITIONS AND METHODS FOR INHIBITION AND TARGETING OF P97 | Final Rejection | California Institute of Technology |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | Final Rejection | Roche Diagnostics Operations, Inc. |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18556237 | HIGH-SENSITIVITY NANOPLASMONIC BIOSENSOR FOR DETECTING AUTOPHAGY MARKERS, MANUFACTURING METHOD THEREFOR, AND AUTOPHAGY MARKER DETECTION METHOD USING SAME | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18451352 | METHOD FOR RESOLVING COMPLEX, MULTISTEP ANTIBODY INTERACTIONS | Final Rejection | Hoffmann-La Roche Inc. |
| 17111946 | DEGRADABLE CARBON NANOTUBE-CONTAINING BIOSENSORS AND METHODS FOR TARGET CLINICAL MARKER DETECTION | Non-Final OA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18566750 | STOOL SPECIMEN TEST METHOD AND IMMUNOCHROMATOGRAPHIC TEST PIECE THEREFOR | Non-Final OA | Denka Company Limited |
| 18572257 | PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND/OR DISEASE AND METHODS OF USE THEREOF | Non-Final OA | BRAINBOX SOLUTIONS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy